Citations

Clear

3042 citation(s) found for "Kumar, S".

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma
Aljama, Mohammed A. , Lakshman, Arjun , Jevremović, Dragan , Lacy, Martha Q. , Dingli, David , Muchtar, Eli , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Warsame, Rahma , Kourelis, Taxiarchis , Hwa, Yi L. , Kapoor, Prashant , Kyle, Robert A. , Kumar, Shaji , Lakshman, Arjun , Muchtar, E , Jevremovic, Dragan , Dingli, David , Sidiqi, M Hasib , Dispenzieri, Angela , Gertz, Morie A. , Buadi, Francis K. , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | November 21, 2018 | Volume: 2 | Issue: 22 | Pages: 3149-3154

10.1182/bloodadvances.2018024794 | PMID 30463914 Get It

Abstract The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26%) patients had an elevated PCPI (>0.5). An elevated PCPI predicted an inferior time to progression (median, 3.0 vs 7.1 years for those with a low PCPI; P = .0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI (49% vs. 20%; P < .0001). PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow-up and consideration of early intervention trials.
Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma
Kumar, Shaji , Grząśko, Norbert , Wiktor-Jędrzejczak, W , Grosicki, Sebastian , Kyrtsonis, Marie‐Christine , Spencer, Andrew , Gupta, Neeraj , Teng, Zhaoyang , Byrne, Catriona , Labotka, Richard, Kumar, Shaji K , Gupta, Neeraj , Dimopoulos, Meletios A , Delimpasi, Sosana , Dimopoulos, Meletios Α.

Mayo Clinic

British Journal of Haematology | November 21, 2018 | Volume: 184 | Issue: 4 | Pages: 536-546

10.1111/bjh.15679 | PMID 30460684 Get It

SummaryThere is a need for efficacious, convenient treatments with long‐term tolerability for patients with relapsed/refractory multiple myeloma (RRMM). This phase 2 study evaluated the all‐oral combination of ixazomib, cyclophosphamide and dexamethasone (ICd). Patients with RRMM received ixazomib 4 mg and cyclophosphamide 300 mg/m2 on days 1, 8 and 15, and dexamethasone 40 mg on days 1, 8, 15 and 22 in 28‐day cycles. The primary endpoint was overall response rate (ORR). Seventy‐eight patients were enrolled (median age 63·5 years). At data cut‐off, patients had received a median of 12 treatment cycles; 31% remained on treatment. ORR was 48% [16% very good partial response or better (≥VGPR)]. ORR was 64% and 32% in patients aged ≥65 and <65 years (25% and 16% ≥VGPR), respectively. At a median follow‐up of 15·2 months, median progression‐free survival (PFS) was 14·2 months, with a trend towards better PFS in patients aged ≥65 years vs. <65 years (median 18·7 months vs. 12·0 months; hazard ratio 0·62, P = 0·14). ICd was well tolerated. The most common treatment‐emergent adverse events were diarrhoea (33%), nausea (24%), upper respiratory tract infection (24%), and thrombocytopenia (22%); 10 patients (13%) had peripheral neuropathy (one grade 3). This study is registered at ClinicalTrials.gov (NCT02046070).
Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin
Kumar, Shaji , Gertz, Morie A. , Dispenzieri, Angela

Mayo Clinic

Journal of Clinical Oncology | November 15, 2018 | Volume: 37 | Issue: 2 | Pages: 171-173

10.1200/jco.18.01398 | PMID 30433848 Get It

Ixazomib for the treatment of multiple myeloma
Richardson, Paul G. , Zweegman, Sonja , O’Donnell, Elizabeth , Laubach, Jacob P. , Voorhees, Peter M. , Ferrari, Renda H., Skácel, Tomáš, Kumar, Shaji , Kumar, Shaji K , Zweegman, Sonja , Richardson, Paul Gerard Guy , Raje, Noopur , Lonial, Sagar

Mayo Clinic

Expert Opinion on Pharmacotherapy | November 14, 2018 | Volume: 19 | Issue: 17 | Pages: 1949-1968

10.1080/14656566.2018.1528229 | PMID 30422008 Get It

Timing of treatment of smoldering myeloma: delay until progression
Kumar, Shaji , Kumar, Shaji K

Mayo Clinic

Blood Advances | November 13, 2018 | Volume: 2 | Issue: 21 | Pages: 3050-3053

10.1182/bloodadvances.2018021238 | PMID 30425069 Get It

Abstract This article has a companion Point by Mateos and González-Calle.
A Real‐time Color Doppler Marker for Echocardiographic Guidance of an Acoustically Active Extracorporeal Membrane Oxygenation Cannula
Bëlohlávek, Marek , Vaitkus, Veronica V. , Fatemi, Mostafa , Grabham, Jason, Sandweiss, Bryan M., Katayama, Minako , Kumar, Viksit, Fatemi, Mostafa , Kumar, Viksit

Mayo Clinic

Journal of Ultrasound in Medicine | November 12, 2018 | Volume: 38 | Issue: 7 | Pages: 1875-1885

10.1002/jum.14859 | PMID 30419612 Get It

B‐mode ultrasound imaging guidance of cannulas can be compromised by noise, artifacts, and echogenicity that is not distinctive from that of surrounding anatomy. We have modified a venovenous extracorporeal membrane oxygenation cannula by embedding piezoelectric crystals into each of its 3 blood flow ports. Each vibrating crystal acoustically interacts with a Doppler imaging signal and produces an instantaneous color marker. The aim of this study was to compare identification of the extracorporeal membrane oxygenation cannula ports by B‐mode imaging versus the color Doppler marker. Unlike B‐mode imaging, the color Doppler marker identified the corresponding port even in highly challenging closed‐chest scans in anesthetized pigs. The method could improve guidance accuracy of cannulas by ultrasound scans.
STEM-08. MODULATION OF RADIATION-INDUCED MESENCHYMAL STEM CELL MIGRATION IN GLIOBLASTOMA
Harrell, Anna , Mondal, Sujan Kumar , Quiñones‐Hinojosa, Alfredo , Ruiz-García, Henry , Sarabia-Estrada, Rachel , Alvarado-Estrada, Keila , Trifiletti, Daniel M.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi245-vi245

10.1093/neuonc/noy148.1015 Get It

Improved utilization of waist‐to‐height ratio in cardiometabolic risk counselling in children: Application of DMAIC strategy
Gupta, Nidhi , Lteif, Aida, Creo, Ana L. , Iqbal, Anoop Mohamed, Pittock, Siobhán T. , Tebben, Peter J. , Hansen, Janet S., Heyrman, Mary, Spee, Rebecca, Scanlan‐Hanson, Lori N. , Kumar, Seema , Creo, Ana , Pittock, Siobhan , Hansen, Janet, Scanlan-Hanson, Lori, Tebben, Peter , Hansen, Janet

Mayo Clinic

Journal of Evaluation in Clinical Practice | October 31, 2018 | Volume: 25 | Issue: 2 | Pages: 300-305

10.1111/jep.13055 | PMID 30378218 Get It

AbstractRationale, aims, and objectivesWaist circumference (WC) and waist‐to‐height ratio (WHtR) are superior surrogate markers of central obesity than body mass index. However, WC is not measured routinely in paediatric clinics. The objective of this study was to implement measurement of WC during routine assessment of children in an ambulatory outpatient clinic setting and subsequent dissemination of cardiometabolic risk counselling in children with central obesity (defined as WHtR ≥0.5).MethodProspective cohort of patients aged 6 to 20 years. Study period was divided into three phases: baseline (3 months), process improvement (2 months), and implementation (6 months). Define‐Measure‐Analyse‐Improve‐Control (DMAIC) strategy was applied. Measurement of WC was implemented as a component of the physical examination in patients. Outcome measures were (1) improvement in frequency of WC measurement and (2) utilization of WHtR in cardiometabolic risk counselling.ResultsWaist circumference was not measured in any patient during baseline phase (n = 551). During process improvement phase, of the total 347 patients, WC was measured in 35% vs target of 30%. In the implementation phase, WC was measured in 37% patients (365 out of 964). Of these 365 patients, 175 (48%) had elevated WHtR, and 73% of them (n = 128) were counselled about their increased cardiometabolic risk.ConclusionsApplication of an evidence‐based DMAIC protocol led to significant improvement in assessment for central obesity in an ambulatory clinic practice and appropriate counselling regarding cardiometabolic risk reduction in children and adolescents with central obesity over an 8‐month period. Meticulous planning and execution, frequent reinforcement, and integrating feedback from the involved multi‐disciplinary team were important factors in successful implementation of this quality improvement project.
P4‐058: VASCULAR CONTRIBUTIONS TO ALZHEIMER'S DISEASE: A SYSTEMS PHYSIOLOGY PERSPECTIVE
Swaminathan, Suresh Kumar, Sarma, Vidur , Curran, Geoffry L., Bruinsma, Tyler J. , Decklever, Teresa, Lowe, Val J. , Kandimalla, Karunya K. , Min, Hoon-Ki Paul , Kalari, Krishna R.

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_27 | Pages: No page available

10.1016/j.jalz.2018.06.2461 Get It

P1‐197: AMYLOID BETA EFFECTS ON INSULIN PERMEABILITY FROM PLASMA TO BRAIN MEASURED BY I‐125 INSULIN SPECT IN APP/PS1 MICE
Swaminathan, Suresh Kumar, Sarma, Vidur , Ahlschwede, Kristen M. , Bruinsma, Tyler J. , Curran, Geoffry L., Decklever, Teresa, Lowe, Val J. , Min, Hoon-Ki Paul , Kandimalla, Karunya K.

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_6 | Pages: No page available

10.1016/j.jalz.2018.06.201 Get It